Rab27A (D7Z9Q) Rabbit mAb #69295
- WB
- IP
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 27 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunofluorescence (Immunocytochemistry) | 1:800 - 1:1600 |
Storage
Protocol
Specificity / Sensitivity
Rab27A (D7Z9Q) Rabbit mAb recognizes endogenous levels of total Rab27a protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Rab27a protein.
Background
Rab27 is a member of the Ras superfamily of small Rab GTPases implicated in exocytosis (1-2). The protein is localized in secretory lysosomes, such as melanosomes in melanocyte or lytic granules in cytotoxic T cells to control exosome secretion pathway (3-5). Rab27 has two isoforms, Rab27a and Rab27b. Rab27a colocalizes with part of CD63 staining vesicles, and Rab27b shows perinuclear distribution. Target knock out studies indicate that the isoforms control different steps of the exosome secretion pathway (6). Rab27a interacts with a wide range of effectors and is involved in multiple steps of exocytosis depending on the effector it associated with and the cell type that is involved (1,2). Rab27a has been shown to be an important player in leukocyte function, cancer metastasis and invasion, and insulin secretion (7-11)
- Fukuda, M. (2013) Traffic 14, 949-63.
- Izumi, T. (2007) Endocr J 54, 649-57.
- Elstak, E.D. et al. (2011) Blood 118, 1570-8.
- Bahadoran, P. et al. (2001) J Cell Biol 152, 843-50.
- Wood, S.M. et al. (2009) Blood 114, 4117-27.
- Ostrowski, M. et al. (2010) Nat Cell Biol 12, 19-30; sup pp 1-13.
- Catz, S.D. (2013) J Leukoc Biol 94, 613-22.
- Herrero-Turrión, M.J. et al. (2008) J Immunol 181, 3793-803.
- Ostenfeld, M.S. et al. (2014) Cancer Res 74, 5758-71.
- Dong, W. et al. (2015) Discov Med 20, 357-67.
- Cazares, V.A. et al. (2014) Traffic 15, 997-1015.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.